| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | APO-1, FAS |
| Conjugate | |
| Formulation | |
| Host | |
| Product Type | |
| Shipping | |
| Storage |
Scientific Background
Human CD95 (APO-1/FAS) is a type I cell surface glycoprotein that is strongly upregulated on activated T cells, B cells, NK cells and thymocytes (1). CD95 plays an important role in programmed cell death or apoptosis (2). Apoptosis appears to be a mechanism for regulating the immune response (3, 4).
Product Description
CHO CellsRecombinant hCD95(Fas)-huIg is a recombinant human fusion protein produced in CHO Cells cells. Molecular Structure: A soluble fusion protein consisting of the mature extracellular (159 aa) domain of human CD95 fused to a linker (4 aa) and human IgG1 Fc + hinge (232 aa), with a (non glycosylated) predicted monomeric molecular weight of 44.3 kd.
Alternative names: APO-1, FAS
Protein Specifications
| Fusion Format | Human IgG Fc Fusion (huIg) |
|---|---|
| Expression System | CHO Cells |
| Molecular Weight | 44.3 kDa |
| Formulation | 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate |
| Storage | Store at 2 - 5°C. Freeze/Thawing is not recommended. |
| Species Reactivity | Human |
| Validated Applications | ELISA |
| Available Conjugates | Biotin, Unconjugated |
✔ Research Use Only (RUO)
Functional Activity
CD95-huIg fusion protein inhibits CD178 mediated apoptosis of Jurkat cells.
Safety & Handling
Research Use Only. Not intended for diagnostic, therapeutic, or clinical use. Handle according to good laboratory practice (GLP). Consult the Safety Data Sheet (SDS) prior to use.
Related Products
Browse our full collection of recombinant proteins and antibodies for immunology and immune checkpoint research.
This protein was expressed in CHO Cells cells. Mammalian expression is critical for this Fc fusion protein because it ensures proper glycosylation and tertiary folding of the extracellular immunoglobulin-like domains, preserving native receptor-binding activity.
Recombinant hCD95(Fas)-huIg has been validated for: ELISA. It is produced as a Human IgG Fc Fusion (huIg), making it suitable as a blocking reagent, binding standard, or functional stimulant/inhibitor in immunology assays.
Recommended storage: Store at 2 - 5°C. Freeze/Thawing is not recommended.. Formulation: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate. Avoid repeated freeze-thaw cycles. If long-term storage is needed, aliquot upon first use.
Species reactivity includes: human. Cross-reactivity was confirmed by functional binding assays (e.g., ELISA and/or FACS) against cells or recombinant proteins from the indicated species.
Available formats include: Biotin, Unconjugated. Conjugated forms are ready-to-use without secondary detection reagents for flow cytometry. Unconjugated (purified) forms can be used with anti-Fc secondary antibodies in ELISA.
Can't Find What You're Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Leukocyte Typing V (S.F. Schlossman, et al, eds.) Oxford University Press, Oxford (1995) p. 1142-1148.
- S. Nagata & P. Golstein (1995) Science 267: 1449-1456.
- S. Nagata & T. Suda (1995) Immunol Today 16: 39-43.
- D.H. Lynch, F. Ramsdell & M.R. Alderson (1995) Immunol Today 16: 569-574.
- H Wajant, (2003) Essays Biochem 39:53-71.
- A. Ackery, M G Fehlings, (2006) J Neurotrauma 23(5): 604-616.
